


Data Sheet

Product Name:	Myristoleic acid
Cat. No.:	CS-0059626
CAS No.:	544-64-9
Molecular Formula:	C ₁₄ H ₂₆ O ₂
Molecular Weight:	226.36
Target:	Apoptosis; Endogenous Metabolite
Pathway:	Apoptosis; Metabolic Enzyme/Protease
Solubility:	10 mM in DMSO



BIOLOGICAL ACTIVITY:

Myristoleic acid, a cytotoxic component in the extract from *Serenoa repens*, induces apoptosis and necrosis in human prostatic LNCaP cells^[1]. **In Vitro:** Myristoleic acid induces both apoptosis (100 µg/mL, 89.5%) and necrosis (100 µg/mL, 81.8%) in LNCaP cells^[1].

Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation^[2].

In Vivo: Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice^[2].

References:

[1]. Xiaoyan Gao, et al. Ozone initiated heterogeneous oxidation of unsaturated carboxylic acids by ATR-FTIR spectroscopy. *Spectrochim Acta A Mol Biomol Spectrosc.* 2019 May 5;214:177-183.

[2]. Jun-Oh Kwon, et al. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2. *Eur J Pharmacol.* 2015 Dec 5;768:189-98.

CAIndexNames:

9-Tetradecenoic acid,(9Z)-

SMILES:

CCCC/C=C\CCCCCCC(O)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA